-
August 19, 2022 Psychedelic Stocks: MindMed and atai Slash their Pipelines, Mydecine CollapsesThe psychedelic renaissance hits a rough patch as major companies look to tighten their belts...
-
August 15, 2022 MindMed Shelves 18-MC for Opioid Use Disorder and Further Cuts PipelineMindMed drops its proprietary ibogaine for opioid addiction research amidst an ongoing shakeup. What is...
-
July 29, 2022 The Real Reason Cybin Bought Entheon’s DMT Clinical TrialIn a rare move Cybin aquires a phase 1 DMT clinical trial from Entheon Biomedical....
-
July 22, 2022 A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 TrialCompass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new...
-
July 1, 2022 Psychedelic Business Spotlight – July 1This week in psychedelic stock news: MindMed downplays delisiting fears; Red Light Holland teams with...
-
June 24, 2022 This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More!This week in psychedelic stock news, there are big patent developments for Compass, MindMed and...
-
June 17, 2022 Psychedelic Business Spotlight – June 17This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin...
-
June 10, 2022 Psychedelic Business Spotlight – June 10This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon;...
-
June 3, 2022 Psychedelic Business Spotlight – June 3This week in psychedelic business news: Cybin moves towards clinical trials; Braxia releases data on...
-
May 27, 2022 Psychedelic Business Spotlight – May 27This week in psychedelic business news: New patents; another Health Canada SAP Approval; and legal...
